ClinicalTrials.gg
Drug

Nilotinib clinical trials

Also written Tasigna and AMN107.

studies test it
134
open now
7
in phase 3
22
first study started
2001

How each study uses nilotinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the nilotinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
29 Oct 2007 · TASIGNA · NDA 022068 (FDA, Drugs@FDA)
European Union
19 Nov 2007 · Tasigna · EMEA/H/C/000798 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Nilotinib
101
AMN107, Tasigna
2
Nilotinib (AMN107)
2

Brand

Tasigna
43
Tasigna 300 mg
1

Development codes

AMN107
42

In one entry with another drug

Given together, or one or the other

Nilotinib, Imatinib
2

Studies by the year they started

134 studies that test it; most in 2009 (16)

Studies that test nilotinib, by start year
YearStudies
20011
20055
20065
20075
200812
200916
201016
20118
20129
201316
20147
20157
20168
20172
20183
20193
20205
20211
20223
20231
20241

By phase

A phase 1/2 study counts in both.

Early Phase 1
3
Phase 1
33
Phase 2
68
Phase 3
22
Phase 4
17
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 56 · Other 78

Novartis Pharmaceuticals (54) · Gruppo Italiano Malattie EMatologiche dell'Adulto (5) · National Cancer Institute (NCI) (4) · Georgetown University (4) · University Health Network, Toronto (3) · Mayo Clinic (2) · Medical College of Wisconsin (2) · Gustave Roussy, Cancer Campus, Grand Paris (2)

Often tested with

Tested in the same studies.

Imatinib (17) · Dasatinib (9) · Paclitaxel (5) · Ruxolitinib (4) · Peginterferon alfa-2b (2) · Bosutinib (2) · Vinblastine (2) · Alpelisib (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 3 phase 3 studies under way

Nilotinib is the comparator. A study of two new drugs counts under both.

  • 2Asciminib · Novartis Pharmaceuticals
  • 1Embibatinib · Jiangsu Hansoh Pharmaceutical Co., Ltd. · next primary completion Jul 2029
Reaching primary completion within a year · 2

Studies that test nilotinib.

Studies

Open first, then newest update. How each study uses nilotinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 134

See all 134 studies that test nilotinib →

Given beside what is tested · 14 — nilotinib is usual care or a partner of the new treatment
As the comparator · 9 — what is tested is compared with nilotinib

Codes

What other systems call nilotinib · ClinicalTrials.gg INT004754

  • MeSH (NLM) C498826nilotinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) F41401512XNILOTINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 662281Confirmed FDA, Wikidata
  • Wikidata Q412327nilotinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C48375NilotinibOne source FDA
  • DrugBank DB04868One source Wikidata

Also registered as nilotinib dihydrochloride dihydrate (UNII WM15I3PF3G), nilotinib hydrochloride anhydrous (UNII K37N7BYX3X · RxNorm 1804015), nilotinib hydrochloride dihydrate (UNII Y37S7HA3BC) and nilotinib hydrochloride monohydrate (UNII 5JHU0N1R6K).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.